SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Satwani P.)
 

Sökning: WFRF:(Satwani P.) > Long-Term Outcomes ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007723naa a2200805 4500
001oai:DiVA.org:uu-346657
003SwePub
008180322s2018 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:137569115
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3466572 URI
0247 a https://doi.org/10.1002/cncr.311142 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1375691152 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Myers, Regina M.u Childrens Hosp Philadelphia, Div Hematol & Oncol, Philadelphia, PA 19104 USA.4 aut
2451 0a Long-Term Outcomes Among 2-Year Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Diffuse Large B-Cell Lymphoma
264 c 2017-11-10
264 1b WILEY,c 2018
338 a print2 rdacarrier
520 a BACKGROUND: Autologous hematopoietic cell transplantation (auto-HCT) is a standard therapy for relapsed classic Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL); however, long-term outcomes are not well described.METHODS: This study analyzed survival, nonrelapse mortality, late effects, and subsequent malignant neoplasms (SMNs) in 1617 patients who survived progression-free for >= 2 years after auto-HCT for cHL or DLBCL between 1990 and 2008. The median age at auto-HCT was 40 years; the median follow-up was 10.6 years.RESULTS: The 5-year overall survival rate was 90% (95% confidence interval [CI], 87%-92%) for patients with cHL and 89% (95% CI, 87%-91%) for patients with DLBCL. The risk of late mortality in comparison with the general population was 9.6-fold higher for patients with cHL (standardized mortality ratio [SMR], 9.6) and 3.4-fold higher for patients with DLBCL (SMR, 3.4). Relapse accounted for 44% of late deaths. At least 1 late effect was reported for 9% of the patients. A total of 105 SMNs were confirmed: 44 in the cHL group and 61 in the DLBCL group. According to a multivariate analysis, older age, male sex, a Karnofsky score < 90, total body irradiation (TBI) exposure, and a higher number of lines of chemotherapy before auto-HCT were risk factors for overall mortality in cHL. Risk factors in DLBCL were older age and TBI exposure. A subanalysis of 798 adolescent and young adult patients mirrored the outcomes of the overall study population.CONCLUSIONS: Despite generally favorable outcomes, 2-year survivors of auto-HCT for cHL or DLBCL have an excess late-mortality risk in comparison with the general population and experience an assortment of late complications.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a autologous hematopoietic cell transplant
653 a diffuse large B-cell lymphoma
653 a Hodgkin lymphoma
653 a late effects
653 a nonrelapse mortality
653 a survival
7001 a Hill, Brian T.u Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA.4 aut
7001 a Shaw, Bronwen E.u Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.4 aut
7001 a Kim, Soyoungu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA.4 aut
7001 a Millard, Heather R.u Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.4 aut
7001 a Battiwalla, Minoou NHLBI, Hematol Branch, Bethesda, MD 20892 USA.4 aut
7001 a Majhail, Navneet S.u Cleveland Clin, Taussig Canc Inst, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA.4 aut
7001 a Buchbinder, Davidu Childrens Hosp Orange Cty, Div Pediat Hematol, Orange, CA 92668 USA.4 aut
7001 a Lazarus, Hillard M.u Case Western Reserve Univ, Univ Hosp Cleveland, Med Ctr, Seidman Canc Ctr, Cleveland, OH 44106 USA.4 aut
7001 a Savani, Bipin N.u Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.4 aut
7001 a Flowers, Mary E. D.u Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.4 aut
7001 a D'Souza, Anitau Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.4 aut
7001 a Ehrhardt, Matthew J.u St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.4 aut
7001 a Langston, Ameliau Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.4 aut
7001 a Yared, Jean A.u Univ Maryland, Dept Med, Div Hematol Oncol, Greenebaum Comprehens Canc Ctr,Blood & Marrow Tra, Baltimore, MD 21201 USA.4 aut
7001 a Hayashi, Robert J.u Washington Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol, St Louis, MO 63110 USA.4 aut
7001 a Daly, Andrewu Tom Baker Canc Clin, Calgary, AB, Canada.4 aut
7001 a Olsson, Richardu Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Div Therapeut Immunol, Dept Lab Med, Stockholm, Sweden4 aut0 (Swepub:uu)riols677
7001 a Inamoto, Yoshihirou Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan.4 aut
7001 a Malone, Adriana K.u Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.4 aut
7001 a DeFilipp, Zachariahu Massachusetts Gen Hosp, Blood & Marrow Transplant Program, Boston, MA 02114 USA.4 aut
7001 a Margossian, Steven P.u Boston Childrens Hosp, Dept Pediat Oncol, Boston, MA USA.;Dana Farber Canc Inst, Boston, MA 02115 USA.4 aut
7001 a Warwick, Anne B.u Uniformed Serv Ind Hlth Sci, Dept Pediat, Bethesda, MD USA.4 aut
7001 a Jaglowski, Samanthau Ohio State Univ, Med Ctr, Div Hematol, Columbus, OH 43210 USA.4 aut
7001 a Beitinjaneh, Ameru Univ Miami, Miami, FL USA.4 aut
7001 a Fung, Henryu Fox Chase Canc Ctr, Dept Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.4 aut
7001 a Kasow, Kimberly A.u Univ N Carolina, Div Hematol Oncol, Dept Pediat, Chapel Hill, NC USA.4 aut
7001 a Marks, David I.u Univ Hosp Bristol NHS Trust, Adult Bone Marrow Transplant, Bristol, Avon, England.4 aut
7001 a Reynolds, Janau Baylor Univ, Med Ctr, Dallas, TX USA.4 aut
7001 a Stockerl-Goldstein, Keithu Washington Univ, Sch Med, Div Oncol, St Louis, MO USA.4 aut
7001 a Wirk, Baldeepu Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA.4 aut
7001 a Wood, William A.u Univ N Carolina, Div Hematol Oncol, Dept Med, Chapel Hill, NC USA.4 aut
7001 a Hamadani, Mehdiu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.4 aut
7001 a Satwani, Prakashu Columbia Univ, Med Ctr, Dept Pediat, Div Pediat Hematol Oncol & Stem Cell Transplantat, New York, NY USA.4 aut
7102 a Childrens Hosp Philadelphia, Div Hematol & Oncol, Philadelphia, PA 19104 USA.b Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA.4 org
7730 t Cancerd : WILEYg 124:4, s. 816-825q 124:4<816-825x 0008-543Xx 1097-0142
8564 u https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.31114
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-346657
8564 8u https://doi.org/10.1002/cncr.31114
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:137569115

Hitta via bibliotek

  • Cancer (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy